Item 7.01 Regulation FD Disclosure.

The information in this report furnished pursuant to Items 2.02 and 7.01 shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Items 2.02 and 7.01 of this report.

At an investor conference on February 12, 2013, Zalicus Inc. (the "Company") will disclose that its unaudited cash, cash equivalents and marketable securities balance as of December 31, 2012 was approximately $36.4 million, that its royalties from net sales of the product Exalgo® by Covidien plc for the Company's fiscal quarter ended December 31, 2012 were approximately $1.5 million and that its revenue from its cHTS™ collaborations for the fiscal year ended December 31, 2012 was approximately $7.3 million.

---